| Quarterly Financials | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
Revenue  | 195 | 165 | 250 | 285 | 208 | 271 | 252 | 330 | 228 | 320 | 261 | 439 | 219 | 263 |
| Expenses | 116 | 122 | 131 | 146 | 123 | 147 | 135 | 187 | 135 | 177 | 146 | 241 | 143 | 159 |
| EBITDA | 79 | 44 | 119 | 139 | 85 | 124 | 117 | 143 | 93 | 144 | 115 | 198 | 77 | 104 |
| Operating Profit % | 36 % | 24 % | 46 % | 47 % | 37 % | 44 % | 44 % | 41 % | 38 % | 43 % | 40 % | 44 % | 30 % | 36 % |
| Depreciation | 14 | 13 | 14 | 14 | 13 | 13 | 14 | 14 | 13 | 13 | 13 | 15 | 18 | 18 |
| Interest | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 64 | 30 | 105 | 124 | 71 | 110 | 103 | 129 | 80 | 130 | 101 | 184 | 59 | 86 |
| Tax | 15 | 8 | 27 | 32 | 17 | 29 | 26 | 34 | 20 | 35 | 25 | 43 | 15 | 23 |
| Net Profit | 49 | 22 | 77 | 92 | 55 | 81 | 78 | 95 | 60 | 96 | 76 | 140 | 44 | 63 |
| EPS in ₹ | 4.71 | 2.10 | 7.40 | 8.75 | 5.21 | 7.74 | 7.41 | 9.08 | 5.70 | 9.15 | 7.26 | 13.42 | 4.21 | 6.03 |
Concord Biotech
Concord Biotech
1,408.40
+6.80
(0.49%)
Market Cap
₹14,734.10 Cr
PE Ratio
46.54
Volume
51,263.00
Day High - Low
₹1,429.80 - ₹1,392.00
52W High-Low
₹2,451.70 - ₹1,345.00
Key Fundamentals
Market Cap
14,734.10 Cr
EPS
35.52
PB Ratio
8.24
Book Value
174.68
EBITDA
550.80
Dividend Yield
0.61 %
Industry
Healthcare Sector
Pharmaceuticals ROE Growth %
-
Debt to Equity
0.00
Analyst Rating and Forecast
- By Refinitiv from4 analysts
Actual
Company News
View All News
Concord Biotech Reports 20% Revenue Decline in Q2 FY26 Due to Regulatory Delays and Market Disruptions
Nov 19, 2025
Nov 19, 2025Concord Biotech's Q2 FY26 revenues dropped to Rs. 247 crores from Rs. 310 crores year-on-year, primarily due to CDSCO written confirmation delays affecting EU sales, deferred Middle East government tender, and US procurement pattern shifts from tariff uncertainties. The company expects stronger H2 performance as regulatory approvals are now received and delayed shipments resume, with EBITDA margins at 41% excluding injectable facility startup costs.
Concord Biotech management anticipates stronger performance in H2 FY26 compared to H2 FY25, with better clarity expected in Q4, while the injectable facility could potentially generate INR 400-600 crores revenue from a total addressable market of INR 3,000-4,000 crores. The company believes it has capabilities to achieve 25% CAGR based on its facilities, product mix, and new facilities that weren't previously contributing, though no formal guidance has been provided.
Concord Biotech reported Q2 net profit of 629 million rupees compared to 987 million rupees year-over-year, with revenue declining to 2.47 billion rupees from 3.1 billion rupees. The company's EBITDA dropped to 905.4 million rupees from 1.36 billion rupees, while EBITDA margin compressed to 36.65% from 44.06% in the same period last year.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,805.30 | #1 4,33,151.90 | 40.68 | #1 54,729.00 | 9.71 | #1 10,980 | 2.89 | 63.65 | |
6,473.50 | 1,71,851.10 | 69.05 | 9,712.00 | 18.67 | 2,191 | 35.10 | 50.10 | |
3,785.90 | 1,28,132.10 | 58.80 | 11,539.40 | 6.99 | 1,911 | 30.46 | 60.01 | |
1,520.80 | 1,22,843.20 | 22.73 | 28,409.50 | 7.12 | 5,291 | 3.71 | 48.01 | |
1,275.20 | 1,06,429.90 | #1 18.15 | 33,741.20 | 16.73 | 5,725 | -0.38 | 61.42 | |
2,098.80 | 95,863.60 | 21.34 | 22,909.50 | 13.74 | 3,306 | #1 72.75 | 67.65 | |
931.45 | 93,725.70 | 18.56 | 23,511.00 | 18.55 | 4,615 | 34.60 | 40.18 | |
2,205.50 | 91,033.90 | 52.05 | 12,744.20 | #1 20.90 | 2,007 | -21.05 | 32.30 | |
1,217.60 | 70,718.40 | 20.70 | 32,345.60 | 9.43 | 3,484 | 3.81 | 58.88 | |
5,675.50 | 67,859.10 | 28.29 | 13,458.30 | 3.70 | 2,216 | 10.98 | 53.12 |
Automatic Screeners on ScanX
Growth Rate
Revenue Growth
18.44 %
Net Income Growth
20.61 %
Cash Flow Change
-7.89 %
ROE
1.59 %
ROCE
0.49 %
EBITDA Margin (Avg.)
-0.07 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2020 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 941 | 1,313 | 1,514 | 1,701 | 2,034 |
| Fixed Assets | 240 | 573 | 593 | 575 | 795 |
| Current Assets | 539 | 633 | 728 | 896 | 1,135 |
| Capital Work in Progress | 141 | 74 | 173 | 212 | 51 |
| Investments | 199 | 74 | 137 | 246 | 335 |
| Other Assets | 361 | 592 | 611 | 668 | 854 |
| Total Liabilities | 941 | 1,313 | 1,514 | 1,701 | 2,034 |
| Current Liabilities | 115 | 155 | 192 | 142 | 184 |
| Non Current Liabilities | 55 | 54 | 32 | 32 | 38 |
| Total Equity | 770 | 1,103 | 1,290 | 1,527 | 1,813 |
| Reserve & Surplus | 761 | 1,094 | 1,280 | 1,516 | 1,802 |
| Share Capital | 10 | 10 | 11 | 11 | 11 |
Cash Flow
| Cash Flow | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | -1 | 3 | -5 | 3 | 12 | -14 |
| Investing Activities | -114 | -195 | -112 | -158 | -155 | -160 |
| Operating Activities | 155 | 167 | 208 | 246 | 266 | 245 |
| Financing Activities | -43 | 31 | -100 | -85 | -99 | -99 |
Share Holding
| % Holding | Aug 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
| Promoter | 44.08 % | 44.08 % | 44.08 % | 44.08 % | 44.08 % | 44.08 % | 44.08 % | 44.08 % | 44.08 % | 44.08 % |
| FIIs | 0.00 % | 7.30 % | 0.00 % | 6.48 % | 7.11 % | 8.10 % | 8.33 % | 9.35 % | 9.11 % | 8.03 % |
| DIIs | 4.89 % | 8.18 % | 8.13 % | 8.46 % | 10.40 % | 9.89 % | 9.66 % | 9.16 % | 8.87 % | 9.55 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 13.33 % | 6.78 % | 6.76 % | 7.08 % | 7.64 % | 7.33 % | 7.33 % | 6.94 % | 7.43 % | 7.77 % |
| Others | 37.69 % | 33.66 % | 41.03 % | 33.90 % | 30.76 % | 30.61 % | 30.59 % | 30.47 % | 30.51 % | 30.56 % |
| No of Share Holders | 3,77,572 | 1,00,927 | 87,486 | 83,296 | 80,737 | 84,298 | 82,004 | 81,219 | 82,045 | 82,650 |
Dividend History
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.83 | 8.75 | 10.7 |
| Dividend Yield (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.45 | 0.52 | 0.76 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 22 Jun 2024 |  Dividend | ₹ 8.75 /share | 21 Jun 2024 | 1,460.10 | 1,559.25 |
| 29 Jun 2024 |  Annual General Meeting | NA | 29 Jun 2024 | 1,460.10 | 1,549.05 |
| 11 Nov 2024 |  Quarterly Result Announcement | NA | 11 Nov 2024 | 1,812.25 | 1,850.00 |
| 13 Feb 2025 | Quarterly Result Announcement | NA | 13 Feb 2025 | 2,125.70 | 2,119.00 |
| 29 May 2025 | Quarterly Result Announcement | NA | 29 May 2025 | 1,532.10 | 1,635.70 |
| 08 Aug 2025 | Quarterly Result Announcement | NA | 08 Aug 2025 | 1,739.70 | 1,633.10 |
| 03 Sept 2025 | Dividend | ₹ 10.70 /share | 03 Sept 2025 | 1,635.70 | 1,691.15 |
| 09 Sept 2025 | Annual General Meeting | NA | 09 Sept 2025 | 1,648.30 | 1,610.20 |
| 13 Nov 2025 | Quarterly Result Announcement | NA | 13 Nov 2025 | 1,394.90 | 1,462.85 |
Announcements
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptNov 19, 2025
Nov 19, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 15, 2025
Nov 15, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 14, 2025
Nov 14, 2025Announcement under Regulation 30 (LODR)-Investor PresentationNov 13, 2025
Nov 13, 2025Financial Results For The Period Ended 30 September 2025Nov 13, 2025
Nov 13, 2025Board Meeting Outcome for Outcome Of Board Meeting Held On 13/11/2025Nov 13, 2025
Nov 13, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 08, 2025
Nov 08, 2025Board Meeting Intimation for Financial ResultsNov 08, 2025
Nov 08, 2025Successful Completion Of NAFDAC InspectionOct 08, 2025
Oct 08, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 06, 2025
Oct 06, 2025Closure of Trading WindowSep 25, 2025
Sep 25, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 11, 2025
Sep 11, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationSep 11, 2025
Sep 11, 2025Shareholder Meeting / Postal Ballot-Scrutinizers ReportSep 11, 2025
Sep 11, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMSep 09, 2025
Sep 09, 2025Successful Completion Of EU GMP InspectionAug 21, 2025
Aug 21, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptAug 18, 2025
Aug 18, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 14, 2025
Aug 14, 2025Business Responsibility and Sustainability Reporting (BRSR)Aug 13, 2025
Aug 13, 2025Reg. 34 (1) Annual Report.Aug 13, 2025
Aug 13, 2025Intimation Of 40Th Annual General Meeting NoticeAug 13, 2025
Aug 13, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 12, 2025
Aug 12, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeAug 11, 2025
Aug 11, 2025Announcement under Regulation 30 (LODR)-Investor PresentationAug 10, 2025
Aug 10, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 10, 2025
Aug 10, 2025Financial Results Q1 FY 2025-2026Aug 08, 2025
Aug 08, 2025Record DateAug 08, 2025
Aug 08, 2025Board Meeting Outcome for Outcome Of Board MeetingAug 08, 2025
Aug 08, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationAug 05, 2025
Aug 05, 2025Board Meeting Intimation for Approval Of Standalone And Consolidated Unaudited Financial Results For The First Quarter Ended On June 30 2025 Along With Limited Review ReportAug 04, 2025
Aug 04, 2025Successful Completion Of Russian GMP InspectionJul 26, 2025
Jul 26, 2025Announcement under Regulation 30 (LODR)-AcquisitionJul 22, 2025
Jul 22, 2025Successful Completion Of EU GMP InspectionJul 18, 2025
Jul 18, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 08, 2025
Jul 08, 2025Announcement under Regulation 30 (LODR)-AcquisitionJul 02, 2025
Jul 02, 2025Closure of Trading WindowJun 25, 2025
Jun 25, 2025Update On The USFDA Inspection At The Companys API Facility At DholkaJun 24, 2025
Jun 24, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJun 06, 2025
Jun 06, 2025Intimation Pursuant To Regulation 30(5) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 (Listing Regulations)Jun 02, 2025
Jun 02, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 02, 2025
Jun 02, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJun 02, 2025
Jun 02, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 31, 2025
May 31, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 30, 2025
May 30, 2025Announcement under Regulation 30 (LODR)-Investor PresentationMay 30, 2025
May 30, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 29, 2025
May 29, 2025Appointment Of AuditorsMay 29, 2025
May 29, 2025Appointment of Company Secretary and Compliance OfficerMay 29, 2025
May 29, 2025Corporate Action-Board approves DividendMay 29, 2025
May 29, 2025Financial ResultMay 29, 2025
May 29, 2025Board Meeting Outcome for Outcome Of Board Meeting Held On 29Th May2025May 29, 2025
May 29, 2025Mutual Fund Holdings
HSBC Small Cap Fund Direct-Growth 
DSP Small Cap Direct Plan-Growth 
SBI Healthcare Opportunities Fund Direct Plan-Growth 
Invesco India Smallcap Fund Direct - Growth 
Edelweiss Small Cap Fund Direct - Growth 
Nippon India Pharma Fund Direct-Growth 
Quant Healthcare Fund Direct - Growth 
Union Small Cap Fund Direct-Growth 
ITI Flexi Cap Fund Direct - Growth 
Canara Robeco Manufacturing Fund Direct - Growth 
Bandhan Midcap Fund Direct-Growth 
Baroda BNP Paribas Multi Cap Fund Direct-Growth 
LIC MF Healthcare Fund Direct - Growth 
ICICI Prudential Nifty Smallcap 250 Index Fund Direct - Growth 
HDFC Nifty Smallcap 250 Index Fund Direct-Growth Technical Indicators
RSI(14)
Neutral 40.76
ATR(14)
Less Volatile 39.50
STOCH(9,6)
Neutral 33.51
STOCH RSI(14)
Neutral 26.16
MACD(12,26)
Bullish 0.82
ADX(14)
Strong Trend 39.88
UO(9)
Bearish 39.56
ROC(12)
Downtrend And Accelerating -2.78
WillR(14)
Oversold -86.11
About Concord Biotech
Concord Biotech Limited is an India-based biopharma company that develops and manufactures fermentation-based APIs and formulations. It focuses on immunosuppressants, oncology, anti-infectives, nephrology, and critical care. The company operates three manufacturing facilities in Gujarat, India, with a total annual installed fermentation capacity of 1,250 m3 for APIs. Concord Biotech supplies products to over 70 countries, including regulated markets like the United States, Europe, and Japan. The company was originally incorporated in 1984, acquired by Sudhir Vaid in 2000, and launched its formulation business in 2016. It went public in August 2023 through an Initial Public Offer.
Listing Date
18 Aug, 2023(2 Years,
-10 days)
Chairperson NameSUDHIR JAIRAM VAID
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
